Gilead Sciences scored a legal victory regarding fraudulent HIV reimbursements. The company secured a court order against a number of clinics, labs and prescribers in Florida that were engaging in the alleged fraud that could be valued in the tens of millions of dollars.
One big task for Gilead Sciences’ HIV franchise in the coming year is to save some $2.5 billion in annual sales by switching as many PrEP patients as possible from Truvada to newly approved Descovy before generics hit.
The escalating global recall of Zantac, the heartburn pill that once ranked as the world’s best-selling drug, has its roots not in government oversight or a high-profile lawsuit, but in a tiny online pharmacy here whose founders feared that U.S. drugs might not be as safe as people think.
Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.
Pharma TV ads seeming familiar lately? That’s in part because the same brands keep buying TV time. For the second month in a row, AbbVie’s Humira, Gilead Sciences' Truvada and Allergan’s Botox took the first, second and third spots on the top 10 pharma spenders list, according to data from real-time TV ad tracker iSpot.tv.
In May, Gilead pledged to donate 2.4 million bottles of its HIV drug Truvada to the U.S. government’s effort to eradicate the disease, partly by preventing new infections. Gilead even promised it would donate its newer drug, Descovy, if the FDA approves it for prevention as it did for Truvada.
Healthy people at risk for HIV should take a daily pill to minimize their chances of getting the virus, according to new guidelines from an influential panel of U.S. physicians.
With HIV rates in the U.S. holding steady, health officials are looking to drugmakers for help containing its spread. Now Gilead Sciences—which has faced its fair share of pricing criticism over the years—is ready to contribute Truvada to the government's infection-fighting effort.
For years, Gilead Sciences has said its antiviral drug Truvada, used to treat and prevent HIV infection, wouldn’t face generic competition until 2021. But Gilead recently—and quietly—moved its generic expectations up a year.
List of centrally authorised products requiring a notification of a change for update of annexes